Saltar al contenido
Merck

C6022

Sigma-Aldrich

Cyproheptadine hydrochloride sesquihydrate

≥98% (TLC), solid

Sinónimos:

Piperidine, 4-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-1-methyl-, hydrochloride, hydrate (2:3)

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C21H21N·HCl·1.5H2O
Número de CAS:
Peso molecular:
350.88
Número CE:
Código UNSPSC:
12352200
ID de la sustancia en PubChem:
NACRES:
NA.77

Análisis

≥98% (TLC)

formulario

solid

color

white to slightly yellow

solubilidad

ethanol: soluble
methanol: soluble

emisor

Merck & Co., Inc., Kenilworth, NJ, U.S.

cadena SMILES

Cl.CN1CCC(\CC1)=C2/c3ccccc3C=Cc4ccccc24

InChI

1S/2C21H21N.2ClH.3H2O/c2*1-22-14-12-18(13-15-22)21-19-8-4-2-6-16(19)10-11-17-7-3-5-9-20(17)21;;;;;/h2*2-11H,12-15H2,1H3;2*1H;3*1H2

Clave InChI

ZEAUHIZSRUAMQG-UHFFFAOYSA-N

Información sobre el gen

¿Está buscando productos similares? Visita Guía de comparación de productos

Aplicación

Cyproheptadine hydrochloride sesquihydrate has been used in:
  • testing anti-inflammatory activity in serotonin receptor (5-HT) induced inflammation
  • the inhibition of 5-HT in in vivo and in vitro bioassays in crabs
  • the inhibition of 5-HT in embryo physiological experiments

inhibition of calcitonin gene related peptide (CGRP)

Acciones bioquímicas o fisiológicas

Cyproheptadine hydrochloride sesquihydrate is a serotonin receptor (5-HT2/5-HT1C) antagonist, H1 histamine receptor antagonist and an antipruritic. The inhibition of 5-HT by cyproheptadine improves cognitive function in schizophrenia disorder. Cyproheptadine is effective for treating functional gastrointestinal disorders (FGIDs). Food and Drug Administration (FDA) approved cyproheptadine, has antidepressant and antiplatelet functionality. It may be effective in treating thromboembolic disorders. Cyproheptadine inhibits lysine methyltransferase 7/9 (Set7/9) leading to a decrease in estrogen receptor (ERα) expression and growth arrest in breast cancer cells.

Características y beneficios

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictogramas

Skull and crossbones

Palabra de señalización

Danger

Frases de peligro

Clasificaciones de peligro

Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Órganos de actuación

Respiratory system

Código de clase de almacenamiento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Clase de riesgo para el agua (WGK)

WGK 3

Equipo de protección personal

dust mask type N95 (US), Eyeshields, Faceshields, Gloves


Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Comparative anticholinergic activities of 10 histamine H1 receptor antagonists in two functional models
Orzechowski RF, et al.
European Journal of Pharmacology, 506(3), 257-264 (2005)
S Kimura et al.
Immunological investigations, 27(6), 379-393 (1998-12-09)
For the immunopharmacological characterization of murine passive anaphylactic shock, the effects of antihistaminics and/or anti-platelet-activating factor (anti-PAF) agents were studied on the shock mediated by allogeneic monoclonal IgE and IgG1 antibodies and hyperimmune serum. IgE antibody-mediated shock was strongly suppressed
The antidepressant 5-HT2A receptor antagonists pizotifen and cyproheptadine inhibit serotonin-enhanced platelet function
Lin OA, et al.
PLoS ONE, 9(1), e87026-e87026 (2014)
Anti-inflammatory activity of bartogenic acid containing fraction of fruits of Barringtonia racemosa Roxb. in acute and chronic animal models of inflammation
Patil KR and Patil CR
Journal of traditional and complementary medicine, 7(1), 86-93 (2017)
E O Okoro
The Journal of pharmacy and pharmacology, 51(8), 953-957 (1999-09-30)
We have previously shown that elimination of buffer Ca2+ markedly reduced maximum 5-HT-induced contractions. We have now investigated the effect of L-type Ca2+-channel blockers and 5-HT2 receptor antagonists on 5-HT- and K+-induced contractions in rat aorta to explore the possibility

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico